Main Menu
Menu

Blog

Publish Date
BlogFact Checks
Fact Check: What Critics Get Wrong About the Patent Eligibility Restoration Act

A coalition of anti-patent groups — including the R Street Institute, the Electronic Frontier Foundation, Public Knowledge, and others — recently sent...

Blog
C4IP Coalition Updates: November 2025

November Highlights: The Upcoming Review of the USMCA This fall marked the beginning of the first scheduled Joint Review process for the...

Blog
This Month in IP: November 2025

Strong, consistent IP protections throughout U.S. history enabled the creation of innovative and useful technologies that we use regularly today. From gardening...

BlogFact Checks
Fact Check: Weakening the patent system won’t lower prices for patients. It would undermine medical progress.

In a recent STAT article, I-MAK CEO Tahir Amin argues that abuses of the patent system are leading to higher drug costs....

Blog
Inventor Spotlight: Ronald Rivest, Adi Shamir, and Leonard Adleman

C4IP is honoring Ronald Rivest (born 1947), Adi Shamir (b. 1952), and Leonard Adleman (b. 1945), whose invention of RSA cryptography forms...

BlogFact Checks
Fact Check: The Data Doesn’t Support the Existence of So-Called Patent “Thickets”

Several academic authors recently published an article in Health Affairs Forefront advising policymakers in Congress and at the USPTO on the best...

Blog
‘Tis the Season — of Counterfeits?

Counterfeiting is a multi-billion-dollar enterprise that puts consumers at serious risk. Poorly-made laptop batteries can overheat. Knock-off cosmetics may contain toxic chemicals....

Blog
This Month in IP: October 2025

Strong, consistent IP protections throughout U.S. history enabled the creation of innovative and useful technologies that we use regularly today. From firefighting...

Blog
C4IP Coalition Updates: October 2025

October Highlights: C4IP Advocates for the Patent Eligibility Restoration Act On October 8, the Senate Judiciary Subcommittee on Intellectual Property held a...

Blog
Why Continued Innovation Matters: Keytruda and the “Product Hopping” Myth

The FDA recently approved a new version of Keytruda, a cancer immunotherapy medicine that is one of the world’s most successful drugs....

BlogFact Checks
Fact Check: The Myth of So-Called “Royalty Free” and “Open” Standards

The word “open” has become increasingly misused in the world of technology standards. In policy and antitrust terms, an open standard is...

Blog
Highlights from the October 8 PERA Hearing

On October 8, the Senate Judiciary Subcommittee on Intellectual Property held a hearing on the Patent Eligibility Restoration Act (PERA) to examine...

Blog:

Blog:

C4IP Coalition Updates: September 2023,

10/04/2023
Blog:

Blog:

This Month in IP: September 2023,

10/04/2023
Blog:

Blog, Fact Checks:

Fact Check: “Reasonable Pricing” Policies Do Not Promote Innovation,

09/22/2023
Op-Eds:

Blog, Op-Eds:

Congress must fix U.S. patent system,

09/22/2023
Op-Eds:

Blog, Op-Eds:

The U.S. is losing its technological edge. Congress must intervene to take it back.,

09/21/2023
Blog:

Blog:

Celebrating American Innovation: Clarence Birdseye,

09/14/2023
Op-Eds:

Blog, Op-Eds:

Two bipartisan bills can revitalize American innovation,

09/07/2023
Blog:

Blog:

C4IP Coalition Updates: August 2023,

09/06/2023
Blog:

Blog:

This Month in IP: August 2023,

09/06/2023
Op-Eds:

Blog, Op-Eds:

Supreme Court has weakened U.S. patents, cue Congress,

09/02/2023
Blog:

Blog:

New Resource: Perspectives on IP and Technology Transfer in the United States,

08/29/2023
Blog:

Blog, Fact Checks:

Fact Check: The Patent Eligibility Restoration Act Does Not Allow Patenting of Naturally-Occurring Genes,

08/23/2023
Scroll to Top